Accelerate post-approval research by streamlining the entire study lifecycle

Paradigm Health’s SPIRE platform streamlines post-approval oncology research with pragmatic, prospective studies embedded in routine care Paradigm Health’s SPIRE platform streamlines post-approval oncology research with pragmatic, prospective studies embedded in routine care. Credit via Shutterstock As oncology therapies mature, post-approval research is essential to supporting regulatory commitments, label expansion, and real-world adoption—often under tight timelines. Yet many post-approval studies still rely on trial models built for investigational drugs, introducing unnecessary complexity, restrictive eligibility, and workflows misaligned with routine care, resulting in slower enrollment, limited representativeness, higher costs, and delayed insights. You will receive an email shortly. Please check your inbox…

Source: Clinical Trials Arena